EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer

• Florent Baty,

  Affiliation Division of Pulmonary Medicine, Cantonal Hospital, St. Gallen, Switzerland

  ⨯
• Sacha Rothschild,

  Affiliation Medical Oncology, University Hospital, Basel, Switzerland

  ⨯
• Martin Früh,

  Affiliation Department of Oncology, Cantonal Hospital, St. Gallen, Switzerland

  ⨯
• Daniel Betticher,

  Affiliation Department of Oncology, Cantonal Hospital, Fribourg, Switzerland

  ⨯
• Cornelia Dröge,

  Affiliation Medical Oncology, University Hospital, Basel, Switzerland

  ⨯
• Richard Cathomas,

  Affiliation Department of Oncology, Cantonal Hospital Graubünden, Chur, Switzerland

  ⨯
• Daniel Rauch,

  Affiliation Medical Oncology, Regional Hospital, Thun, Switzerland

  ⨯
• Oliver Gautschi,

  Affiliation Medical Oncology, Cantonal Hospital, Luzern, Switzerland

  ⨯
• Lukas Bubendorf,

  Affiliation Institute of Pathology, University Hospital, Basel, Switzerland

  ⨯
• Susanne Crowe,

  Affiliation Coordinating Center, Swiss Group for Clinical Cancer Research, Bern, Switzerland

  ⨯
• Francesco Zappa,

  Affiliation Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  ⨯
• Miklos Pless,

  Affiliation Department of Oncology, Cantonal Hospital, Winterthur, Switzerland

  ⨯
• Martin Brutsche ,

  * E-mail: martin.brutsche@kssg.ch

  Affiliation Division of Pulmonary Medicine, Cantonal Hospital, St. Gallen, Switzerland

  ⨯
• Swiss Group for Clinical Cancer Research

  ¶Membership of the Swiss Group for Clinical Cancer Research is provided in the Acknowledgments.

  ⨯